Building resilience: City-hotel collaborations for future-proof destinations

Tourism is vital to cities. One of the fastest-growing sectors in urban economies, it is estimated to create 126 million net new jobs by 2032 globally, both in and outside of cities. Additionally, tourism stimulates infrastructure development and economic growth. For those reasons, many mayors would like to see the tourist sector in their cities flourish and expand.But tomorrow's urban tourism must be different from today's. Both city governments and the tourism industry have largely focused on driving up visitor numbers and spending. The resulting seasonal waves of urban tourists in several host cities now pose serious social and environmental concerns, such as housing shortages and congestion, which create more challenges for city mayors. C40 mayors are working to halve their collective emissions by 2030, yet today's urban tourism is still carbon-intensive. The very success of today's low-cost, high-volume tourism is not compatible with the necessary degree of mitigation and adaptation action required to achieve collective targets.City mayors and tourist businesses, particularly hotels, could be allies in the fight against climate change. Both urgently need to keep host cities attractive to residents and visitors while building their resilience to the effects of climate change. That gives both a common interest in crafting new, sustainable models of tourism that bolster resilience, making cities more attractive. Growing media attention on the environmental and climate downsides of today's urban tourism adds pressure on both sides for action now. Collaboration between cities and hotels offers a route to the rapid, creative solutions that both need.This paper shows why and how public-private collaborations between cities and hotels can be used to test and scale solutions to their intersecting challenges. Tourism cuts across many city systems, notably transport, accommodation, food and water. Working with their tourism industry partners, city leaders can shape a competitive landscape for urban tourism in which sustainable tourism becomes the new normal, with hotels leading to ambitious place-based climate action

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Evaluation of tarsal injuries in C57BL/6J male mice.

Tarsal joint abnormalities have been observed in aged male mice on a C57BL background. This joint disease consists of calcaneal displacement, inflammation, and proliferation of car- tilage and connective tissue, that can progress to ankylosis of the joint. While tarsal pathol- ogy has been described previously in C57BL/6N substrains, as well as in STR/ort and B10. BR strain, no current literature describes this disease occurring in C57BL/6J mice. More importantly the behavioral features that may result from such a change to the joint have yet to be evaluated. This condition was observed in older male mice of the C57BL/6J lineage, around the age of 20 weeks or older, at a frequency of 1% of the population. To assess potential phenotypic sequela, this study sought to evaluate body weight, frailty assessment, home cage wheel running, dynamic weight bearing, and mechanical allodynia with and with- out the presence of pain relief with morphine. Overall mice with tarsal injuries had signifi- cantly higher frailty scores (p\u3c 0.05) and weighed less (p\u3c0.01) compared to unaffected mice. Affected mice had greater overall touch sensitivity (p\u3c0.05) and they placed more weight on their forelimbs (p\u3c0.01) compared to their hind limbs. Lastly, when housed with a running wheel, affected mice ran for a shorter length of time (p\u3c0.01) but tended to run a greater distance within the time they did run (p\u3c0.01) compared to unaffected mice. When tested just after being given morphine, the affected mice performed more similarly to unaf- fected mice, suggesting there is a pain sensation to this disease process. This highlights the importance of further characterizing inbred mouse mutations, as they may impact research programs or specific study goals

FASA Fire Airborne Spectral Analysis of natural disasters

At present the authors are developing the system FASA, an airborne combination of a Fourier Transform Spectrometer and an imaging system. The aim is to provide a system that is usable to investigate and monitor emissions from natural disasters such as wild fires and from volcanoes. Besides temperatures and (burned) areas FASA will also provide concentration profiles of the gaseous combustion products. These data are needed to improve the knowledge of the effects of such emissions on the global ecosystem. The paper presents a description of the instrumentation, the data evaluation procedure and shows first results of retrieval calculations based on simulated spectra

Interleukin-6 trans signalling enhances photodynamic therapy by modulating cell cycling

Photodynamic therapy (PDT) of solid tumours causes tissue damage that elicits local and systemic inflammation with major involvement of interleukin-6 (IL-6). We have previously reported that PDT-treated cells lose responsiveness to IL-6 cytokines. Therefore, it is unclear whether PDT surviving tumour cells are subject to regulation by IL-6 and whether this regulation could contribute to tumour control by PDT. We demonstrate in epithelial tumour cells that while the action of IL-6 cytokines through their membrane receptors is attenuated, regulation by IL-6 via trans-signalling is established. Soluble interleukin-6 receptor-α (IL-6Rα) (sIL-6Rα) and IL-6 were released by leucocytes in the presence of conditioned medium from PDT-treated tumour cells. Cells that had lost their membrane receptor IL-6Rα due to PDT responded to treatment with the IL-6R–IL-6 complex (Hyper-IL-6) with activation of signal transducers and activator of transcription (STAT3) and ERK. Photodynamic therapy-treated cells, which were maintained during post-PDT recovery in presence of IL-6 or Hyper-IL-6, showed an enhanced suppression of proliferation. Cytokine-dependent inhibition of proliferation correlated with a decrease in cyclin E, CDK2 and Cdc25A, and enhancement of p27kip1 and hypophosphorylated Rb. The IL-6 trans-signalling-mediated attenuation of cell proliferation was also effective in vivo detectable by an improved Colon26 tumour cure by PDT combined with Hyper-IL-6 treatment. Prevention of IL-6 trans-signalling using soluble gp130 reduced curability. The data suggest that the post-PDT tumour milieu contains the necessary components to establish effective IL-6 trans-signalling, thus providing a means for more effective tumour control